NAD+ buying guide
Is NAD+ a peptide? No. It’s a dinucleotide, with no amino acids in it
No. A peptide is a chain of amino acids, and NAD+ contains none: it’s a dinucleotide, a nicotinamide nucleotide and an adenosine nucleotide joined through their phosphate groups. It sits beside peptides on storefronts because it reaches buyers the same way, compounded by pharmacies and injected, under an FDA compounding list that files both.
What a peptide is, and what NAD+ is made of
A peptide is a chain of amino acids. The National Library of Medicine’s definition leaves no room: “Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures.” Chains of roughly 2 to 12 are oligopeptides. Longer ones are polypeptides.
NAD+ has no amino acids in it. Here is the same library’s description: “A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.” Put plainly, that’s two nucleotides, one built around nicotinamide and one around adenine, joined through their phosphates. It’s what the word dinucleotide in its full name, nicotinamide adenine dinucleotide, is telling you.
| Property | A peptide | NAD+ |
|---|---|---|
| Built from | Amino acids | A nicotinamide nucleotide coupled to an adenosine nucleotide; in MeSH’s words, “ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate” |
| Held together by | Peptide bonds between neighboring amino acids | A pyrophosphate linkage |
| Size | About 2 to 12 amino acids for an oligopeptide, 13 or more for a polypeptide | One fixed molecule, C21H27N7O14P2, molecular weight 663.4 |
| Amino acids in it | Every link in the chain | None |
| Where MeSH files it | Amino Acids, Peptides, and Proteins | Enzymes and Coenzymes; Nucleic Acids, Nucleotides, and Nucleosides |
The plus sign is chemistry, not branding. It marks the oxidized form, the one that becomes NADH when it takes up electrons.
Source: MeSH descriptors Peptides and NAD, U.S. National Library of Medicine; PubChem compound 5892. Read in September 2026.
PubChem lists NAD+ as one compound with one formula, C21H27N7O14P2, and a molecular weight of 663.4. The P2 in that formula is the pair of phosphates holding the two halves together.
Where the reference books file it
MeSH, the National Library of Medicine’s subject vocabulary, places every term on a tree. Peptides sit at one address, D12.644, inside “Amino Acids, Peptides, and Proteins”. NAD sits at four, and not one of them is in that branch. It’s filed under “Enzymes and Coenzymes”, and under “Nucleic Acids, Nucleotides, and Nucleosides” as an adenine nucleotide.
A vocabulary built to sort compounds by what they are doesn’t put NAD+ anywhere near the peptides. It puts it with the coenzymes, for the jobs it does inside every cell.
Why it’s sold beside peptides
Because the shelf is the same. Injectable NAD+ is compounded, and FDA’s list of bulk substances nominated for compounding sorts them by regulatory status, not by chemistry. Its Category 1, “Bulk Drug Substances Under Evaluation”, holds NAD and NADH on the same page as vasoactive intestinal peptide. A list organized that way has no reason to keep a coenzyme and a peptide apart.
Sellers’ own pages show the overlap too: 6 of the 110 sellers in this index publish their NAD+ price on a page whose address or price line files it under peptides: ElitePhysiqMD, Meto, REMEVi, RxPepsDirect, Taurus Meds, and Youth & Soul. And 166 of the 382 prices here are for NAD+ injected under the skin.
It’s the shared shelf, not shared chemistry, that puts the two words in one search.
What the label changes about regulation
FDA draws a line through amino-acid chains in its rules for biological products: “A protein is any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size.” A shorter chain isn’t a protein under that rule. NAD+ isn’t a chain of amino acids of any length, so the line never touches it.
Compounding law is what governs it. FDA says it “does not intend to take regulatory action” against a section 503A pharmacy compounding with a substance that has no USP or NF monograph and isn’t a component of any FDA-approved drug, as long as, among other conditions, the substance is on Category 1. NAD is. That’s the policy that lets a 503A pharmacy compound it now.
Category 1 is a waiting room, not a verdict. FDA describes the substances in it as ones that “may be eligible for inclusion on the 503A bulks list”, nominated with enough information to evaluate. When an evaluation is finished, FDA says it will take its review to the Pharmacy Compounding Advisory Committee for advice on whether the substance belongs on the list.
What it changes about the price
A compounded product has no approved reference to be priced against, so each seller sets its own figure and prints it in its own shape. In this index, 43 of the 110sellers publish a standing monthly rate for NAD+; those 59 rates run from $60 to $299 a month, source readings September 2026 to October 2026, and the median of them is $179. The rest publish a different kind of figure, such as a floor or a first-month price, or nothing that resolves to a price.
When NAD+ is sold inside a plan with other compounds, the price stops being an NAD+ price at all. One figure for several products can’t be split, and those bundle prices are recorded as unresolved rather than guessed at. The sellers with a standing rate are laid out one by one on the NAD+ price index.
What FDA hasn’t decided yet
Whether NAD stays compoundable. It has a category, not a decision.
Will FDA put NAD+ on the list of substances pharmacies may compound with, or refuse it? It has sat in the under-evaluation category with no decision published.
An FDA proposed or final rule naming NAD among the substances placed on, or evaluated and not placed on, the 503A bulks list, after FDA presents its review to the Pharmacy Compounding Advisory Committee. FDA's category list printed May 14, 2026 still has NAD in Category 1, under evaluation.
Read next
About this page
Nothing here is medical advice, diagnosis or treatment. This is a price index, and pages like this one exist because a reader cannot judge a price without knowing what the thing is. Talk to a licensed clinician before starting or stopping anything, and see the medical disclaimer.
Document sources read September 2026. The references below retain each source reading date and the date printed on the document itself. An editorial revision does not refresh those source records. If something here is wrong, the corrections page says how that gets fixed and what has been fixed before.
Sources
- MeSH descriptor: Peptides
- MeSH descriptor: NAD
- Compound summary: Nadide (CID 5892) — computed properties
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act — Guidance for Industry
- 21 CFR 600.3 — Definitions (biological products)